Table 1.

Analysis of response in patients with favorable, intermediate, and adverse-risk rrAML

Risk assessmentORR/CR, favorable risk profile, % (n)ORR/CR, intermediate risk (I + II) profile, % (n)ORR/CR, adverse risk profile, % (n)P value (ORR/CR)
Risk classification
 ELN 201022.2/0 (9)55.8/32.6 (43)30.0/10.0 (20).7322/.8493
 ELN 201737.5/0 (8)65.2/43.5 (23)34.1/14.6 (41).2049/.5816
 Grimwade33.3/0 (6)66.7/58.3 (12)40.7/16.7 (54).6121/.4487
Molecular classification
Papaemmanuil*80.0/60.0 (5)36.4/9.0 (11)42.8/21.4 (56).4631/.2605
  • ORR (CR, CRi, CRp, MLFS, and PR) by risk assessment is based on cytogenetic testing, and mutations are identified by FoundationOne Heme panel according to ELN 2010,29 ELN 2017,28 Grimwade et al,26 and Papaemmanuil et al.13

  • * Papaemmanuil risk was inferred from survival analysis of molecular classifications in which the mCEBPA and mIDH2-R172 groups were considered favorable; mNPM1 and others were considered intermediate; and chromosome 3 inversion, Chromatin-Spliceosome, MLL fusions, and mTP53-aneuploidy were considered adverse.

  • P values were for the contingency test for the logical trend from favorable to adverse risk.